

UC Santa Cruz

UC Santa Cruz Previously Published Works

Title

Thermodynamically coupled biosensors for detecting neutralizing antibodies against SARS-CoV-2 variants

Permalink

<https://escholarship.org/uc/item/1b11v74r>

Journal

Nature Biotechnology, 40(9)

ISSN

1087-0156

Authors

Zhang, Jason Z

Yeh, Hsien-Wei

Walls, Alexandra C

et al.

Publication Date

2022-09-01

DOI

10.1038/s41587-022-01280-8

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed



OPEN

Thermodynamically coupled biosensors for detecting neutralizing antibodies against SARS-CoV-2 variants

Jason Z. Zhang^{1,2,14}✉, Hsien-Wei Yeh^{1,2,14}, Alexandra C. Walls¹, Basile I. M. Wicky^{1,2}, Kaitlin R. Sprouse¹, Laura A. VanBlargan³, Rebecca Treger⁴, Alfredo Quijano-Rubio^{2,5}, Minh N. Pham^{1,2}, John C. Kraft^{1,2}, Ian C. Haydon², Wei Yang^{1,2}, Michelle DeWitt², John E. Bowen¹, Cameron M. Chow², Lauren Carter², Rashmi Ravichandran², Mark H. Wener⁴, Lance Stewart², David Veessler^{1,6}, Michael S. Diamond^{3,7,8,9}, Alexander L. Greninger^{4,10}, David M. Koelle^{4,10,11,12,13} and David Baker^{1,2,6}✉

We designed a protein biosensor that uses thermodynamic coupling for sensitive and rapid detection of neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in serum. The biosensor is a switchable, caged luciferase-receptor-binding domain (RBD) construct that detects serum-antibody interference with the binding of virus RBD to angiotensin-converting enzyme 2 (ACE-2) as a proxy for neutralization. Our coupling approach does not require target modification and can better distinguish sample-to-sample differences in analyte binding affinity and abundance than traditional competition-based assays.

With the availability of coronavirus disease 2019 (COVID-19) vaccines, the rise of more transmissible and pathogenic virus mutants¹ and known time-dependent declines in immunity following infection², there is a need to determine the degree of serological antibody protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Knowledge of individual immunity to SARS-CoV-2 is useful not only to determine personal actions but also to guide early therapy of patients and evaluate the efficacy of antibody treatment and vaccines over time against emerging viral variants of concern (VOCs)³.

The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein binds to the angiotensin-converting enzyme 2 (ACE-2) receptor on target cells and is the immunodominant target of neutralizing antibodies (nAbs) identified from convalescent and post-vaccination plasma³. Several SARS-CoV-2 VOCs have exploited this and acquired mutations in the RBD, which allow for escape from nAbs targeting wild-type⁴ (WT; Wuhan-Hu-1 SARS-CoV-2). Serological antibody tests (ideally home-based diagnostics) are critical to evaluate the response to vaccination and viral infection². Assays that measure antibody titer and neutralizing capability exist

but are not compatible with home use. Traditional affinity-based immunoassays, such as enzyme-linked immunosorbent assays (ELISAs)⁵, can quantitatively measure antibody titer, but due to inherent complexity and instrumentation, they require a centralized laboratory for diagnostics. Antibody neutralizing capabilities are traditionally measured in cell-based live viral infection assays that require BSL3 facilities⁶. Lateral-flow antigen tests have been introduced, but they are used primarily as binary qualitative tests and report only binding between antibody and antigen rather than neutralization⁷. Recently developed cell-free tools can measure antibody titers but cannot necessarily evaluate neutralization, and none of the currently available tools have estimated neutralization activity against the emerging set of SARS-CoV-2 VOCs⁸. We aimed to develop a sensor technology that can quantitatively measure nAb responses against different isolates of SARS-CoV-2, be adapted for an all-in-solution multiwell format and provide rapid results in 1 hour, which is faster than established ELISA assays measuring SARS-CoV-2 antibody titer (~6 hours) or cell-based neutralization assays (~one to several days).

Design of the lucCageRBD assay

To achieve this goal, we designed an assay that focuses on antibodies competing with RBD:ACE-2 interactions as a proxy for antibody neutralization⁸ (Fig. 1a,b). We adapted a designed coronavirus spike RBD biosensor⁹ consisting of a switchable lucCageRBD protein containing a 'cage' domain, which in the closed state of the sensor binds a 'latch' domain containing the picomolar affinity RBD binding LCB1 protein¹⁰, and a lucKey protein that binds to the open state of the sensor, reconstituting luciferase activity¹¹. In the absence of RBD, the sensor is in the closed state with the latch bound to the cage, blocking luciferase reconstitution. Upon addition of RBD,

¹Department of Biochemistry, University of Washington, Seattle, WA, USA. ²Institute for Protein Design, University of Washington, Seattle, WA, USA.

³Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA. ⁴Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA, USA. ⁵Department of Bioengineering, University of Washington, Seattle, WA, USA. ⁶Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA. ⁷Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, USA.

⁸Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA. ⁹Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, Saint Louis, MO, USA. ¹⁰Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. ¹¹Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA. ¹²Translational Research Program, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA.

¹³Department of Global Health, University of Washington, Seattle, WA, USA. ¹⁴These authors contributed equally: Jason Z. Zhang, Hsien-Wei Yeh.

✉e-mail: jason.zhang0428@gmail.com; dabaker@uw.edu

the free energy of binding to lucCageRBD, together with that of lucKey, drives switch opening and generation of luminescent signal (Fig. 1b). Because the biosensor is under thermodynamic control and fully reversible, it is capable of detecting RBD-targeted SARS-CoV-2 antibodies that compete with LCB1 at or near the ACE-2 binding interface of RBD. Starting from the open luminescent state of the sensor bound to the RBD, addition of antibody pulls the equilibrium toward the dark closed state (Fig. 1b).

Unlike previously described competition assays that directly assess the extent of ACE-2:RBD complex formation (by luciferase reconstitution or capturing of enzyme conjugated to one component) (Fig. 1d), in this thermodynamic coupling scheme, the RBD is unmodified and free in solution. This simplifies testing reactivity against RBD VOCs, because no labeling or further sensory protein engineering is required. A more fundamental advantage, as illustrated by the simulations in Fig. 1e and Extended Data Fig. 1, is that compared to ternary sensor systems that rely on direct competition of the ACE-2–RBD interaction by nAbs, our quaternary sensor system can more readily distinguish analyte binding affinity and abundance, both of which are relevant for diagnosing the success of vaccination. The robustness of the quaternary sensor lies in its tunable sensitivity to detect the abundance/dissociation constant (K_d) of unknown antibodies in serum or plasma samples and is the first step of the lucCageRBD assay setup. This step requires pretesting different configurations or evaluating simultaneously several configurations to determine the fraction decrease using different dynamic ranges (as described in the decision matrix in Fig. 1e). Distinguishing signals due to higher concentrations of more weakly binding analytes from those due to lower concentrations of more strongly binding analytes is challenging for the simple outcompetition system, because disruption of the ACE-2:RBD complex (and hence detection) is affected by the concentration and affinity of the competitor to the same proportional extent. Taking measurements for different configurations of the quaternary sensor system (changing the concentrations of the RBD and lucKey sensor components) generates decision matrices (Fig. 1e) that better discriminate analyte concentration and affinity across a broad range of values, including the constant [concentration]/ K_d regime that cannot be discriminated by the ternary sensor (sensor activation across the full analyte affinity and concentration ranges are shown in Extended Data Fig. 1). Another advantage of our quaternary system is that the maximum raw sensor response in the absence of nAb (used for signal normalization; decision matrices at the far right in Fig. 1e) varies less between the different sensor configurations than in the ternary system, because the concentration of the limiting component for signal generation (lucCageRBD) is constant; variation in maximum signal is a problem for luminescent (or other enzyme coupled) sensors because of substrate depletion effects and instrument detection limits. This variation in maximum


signal can be reduced in the ternary system if one component is kept fixed; however, in this case, the high-affinity/low-concentration and low-affinity/high-concentration regimes are even harder to resolve (Extended Data Fig. 1g,h). Substituting ACE-2 for a higher-affinity RBD binder like LCB1 does not alleviate this problem. Finally, our quaternary system is considerably more engineerable. The affinities of the Latch and Key for the Cage can both be tuned to maximize the dynamic range of the system for the relevant analyte affinities and concentrations, whereas to tune response in the ternary system, only mutations at the interface between the interacting partners can be made, which may be insufficient to obtain the desired detection range.

LucCageRBD assay estimates neutralization potency of mAbs

To characterize the quaternary sensor system experimentally, we investigated the modulation of lucCageRBD signal by combinations of RBD (and RBD variants) and RBD binding proteins. Addition of 333 pM RBD to the sensor resulted in a rapid ($t_{1/2} = 22$ min) fivefold increase in luminescence from baseline, which was rapidly quenched ($t_{1/2} = 10$ min) by subsequent addition of 200 nM LCB1, which competitively inhibits RBD binding to the RBD sensor (Extended Data Fig. 2). LucCageRBD also detects Alpha, Beta and Delta RBDs (Extended Data Fig. 3) and the interaction of these proteins with nAbs, such as the Delta-nAb SPD-M162 (Fig. 1f), a validated anti-SARS-CoV-2 spike RBD IgM. To quantify the extent of binding of a competitor antibody or other RBD binding protein, we used as a metric the fraction decrease in total sensor dynamic range (Fig. 1b; this is also used in the simulations above). As predicted by the model, half-maximal effective concentration (EC_{50}) values for lucCageRBD detection of the neutralizing mAb CV30 (ref. ¹²) increase with increasing RBD concentration and decrease with increasing sensor concentration (maintaining 1:1 stoichiometry with RBD) (Extended Data Fig. 4), illustrating how changing RBD and sensor concentrations can tune the sensitivity of the lucCageRBD assay.

To evaluate the detection of nAbs through equilibrium perturbation of the lucCageRBD:RBD system, we compared binding to the spike, virus neutralization (live virus for Fig. 1i,j), pseudovirus for Fig. 1o and Extended Data Fig. 5c,f), and sensor activation over a set of five anti-spike mAbs (SARS2-02, SARS2-38, CV30, B38 and CR3022)^{13–16} for the WT, Alpha, and Beta spike variants (Fig. 1g–o and Extended Data Fig. 5), one of which (CR3022) does not interfere with ACE-2–RBD interaction¹⁵ and accordingly has little effect in the lucCageRBD assay (Fig. 1m). Over this set of antibodies and spike variants, virus neutralization correlates with sensor activation better than with spike binding affinity (Extended Data Fig. 5g–i), as expected, because the sensor is only sensitive to binding near the ACE-2 binding site which is the target of most

Fig. 1 | Design and characterization of sensors for mAb detection. **a**, To detect nAbs that primarily block the interaction between ACE-2 and the RBD of SARS-CoV-2 spike WT and other emerging variants, we designed our lucCageRBD assay, which uses the RBD sensor and lucKey. **b–d**, Schematic and workflow of the LOCKR nAb biosensor system (quaternary, this work) (**b** and **c**) and ACE-2:RBD outcompetition format (ternary, previous work) (**d**). The RBD sensor contains two domains that interact, the Cage and Latch, the latter of which contains small NanoLuc binary technology (smBiT) of luciferase (blue) and the de novo LCB1 domain (yellow) designed to recognize the ACE-2 binding region of RBD. lucKey contains the Cage-associating key domain and large NanoLuc binary technology (lgBiT) of luciferase (blue). RBD WT or variants bind to LCB1, which together with Key–Cage binding enables reconstitution of luciferase, thus increasing luminescence. nAbs compete for RBD binding, thus shifting for Cage–Latch binding, limiting Key–Cage interaction and disturbing luciferase reconstitution, thus decreasing luminescence. As increasing nAb concentrations should promote decreases in luminescence, we created the fraction of lucCageRBD dynamic range lost metric. **e**, Simulations for the detection and deconvolution of nAb titer from affinity. Each sub-plot represents the sensor's responses across the different settings of the decision matrix, which is defined by a combination of lucKey and RBD concentrations (quaternary system; left) or ACE-2 and RBD concentrations (ternary system; right). For each sensor system, the raw maximum signal (absence of nAb, used for signal normalization) is also shown (blue heat maps). **f–o**, Different concentrations of SPD-M162 (**f**), SARS2-02 (**g–i**), SARS2-38 (**j–l**) or CR3022 (**m–o**) mAbs with 5 nM RBD WT, Alpha, Beta or Delta were tested in the lucCageRBD assay (**f,g,j** and **m**), BLI for binding to RBD isolates (**h,k** and **n**) and spike VOC-containing SARS-CoV-2 live virus (**i** and **l**) or vesicular stomatitis virus (VSV)-based pseudovirus infection (**o**). The lucCageRBD and BLI experiments were performed in triplicate, viral infection experiments were performed in duplicate and data are mean \pm s.e.m.






Fig. 2 | Detection of nAbs in clinical samples. a–d, Serum from convalescent or vaccinated patients (positive samples, $n = 40$ for WT, $n = 36$ for Delta) and pre-2019 samples (negative samples, $n = 24$ for both WT and Delta) were collected and tested in the lucCageRBD assay at the indicated dilutions (**a** and **c**) and pseudovirus infection (**b** and **d**) against both WT and Delta RBD/spike. **a**, Associated sensitivity, specificity, positive predictive value and negative predictive value statistics are in Supplementary Table 2 and were calculated with 3 s.d. above negative sample mean (dotted line in **a** and **c**) as the predictive cutoff. **b**, 2% dilution, $R^2 = 0.686$, Pearson's $r = 0.828$; 0.4% dilution, $R^2 = 0.522$, Pearson's $r = 0.722$. **d**, 10% dilution, $R^2 = 0.807$, Pearson's $r = 0.898$; 2% dilution, $R^2 = 0.755$, Pearson's $r = 0.869$, **** $P < 0.0001$, two-tailed Student's t test. **a**, 2% dilution, **** $P = 3.84 \times 10^{-38}$; 0.4% dilution, 5.5×10^{-23} . **c**, 10% dilution, **** $P = 4.28 \times 10^{-17}$; 2% dilution, **** $P = 3.21 \times 10^{-12}$. Viral infection experiments were performed in duplicate and data are mean \pm s.e.m.

nAbs. As an example, the SARS2-02 antibody binds (by biolayer interferometry (BLI)) Beta and WT RBD (Fig. 1h) with roughly equal affinities, but neutralizes infectious SARS-CoV-2 (live virus) containing WT and Alpha spike proteins much more potently (20- to 40-fold increase in half-maximum inhibitory concentration (IC_{50})) than Beta spike-containing virus¹³ (Fig. 1i). Consistent with the neutralization results, the SARS2-02 antibody produces a large decrease in lucCageRBD signal with WT and Alpha RBD but a partial response with Beta RBD (EC_{50} ~40-fold increased) (Fig. 1g and Supplementary Table 1). To confirm the ability to differentiate nAb concentration and affinity suggested by the simulations in Fig. 1e, we assayed two antibodies (CV30 and B38) with different affinities for WT RBD at two different concentrations each, using four different sensor settings, and found that the differential sensor readings for each condition were consistent with the computational model (Extended Data Fig. 1i,j).

LucCageRBD assay robustly detects nAbs in complex samples, including clinical samples

We next investigated whether the correlation between sensor response and neutralizing activity observed over the panel of monoclonal antibodies (mAbs) held for polyclonal antibodies in

serum. As complex biological matrices can affect absolute luminescent readings, we used Antares2 as a BRET reference for internal calibration, and used as a measure of sensor activation the ratio of luminescence signal to the internal standard¹¹ (Methods). Before vaccination, mouse serum samples¹⁷ did not decrease activation, whereas serum samples after prime dosing (week 3) and after boost dosing (week 5) showed progressively larger decreases in activation. Decreases in the luminescence ratio correlate ($R^2 = 0.711$) with the $\log_{10} IC_{50}$ values against WT spike-presenting pseudovirus (Extended Data Fig. 6a) and the \log_{10} reciprocal EC_{50} titer measured in ELISA ($R^2 = 0.917$) (Extended Data Fig. 6b). In serum samples from humans vaccinated with BNT162b2 against WT, Alpha and Beta RBD, the lucCageRBD loss in dynamic range correlates with the SARS-CoV-2 (WT) antibody titer detected from ELISA using the \log_{10} of the Z-score metric (Extended Data Fig. 6d) ($R^2 = 0.942$) and with $\log_{10} IC_{50}$ values against pseudovirus displaying either WT ($R^2 = 0.832$), Alpha ($R^2 = 0.89$) or Beta spike ($R^2 = 0.961$) proteins (Extended Data Fig. 6c). We next evaluated lucCageRBD responses over 40 samples containing SARS-CoV-2 nAbs from persons convalescent, vaccinated or both with a broad range of titers and 24 pre-2019 samples against different SARS-CoV-2 VOCs and dilutions (Fig. 2 and Supplementary Table 2). For both WT and Delta RBD,

the lucCageRBD assay positively correlates with the SARS-CoV-2 antibody titer detected from cell-based pseudovirus neutralization experiments (Fig. 2b,d and Extended Data Fig. 7) and ELISA (Extended Data Fig. 8), and the discrimination between pre- and post-COVID exposure was nearly perfect for both WT and Delta versions of the sensor (Fig. 2a,c), with weaker potency generally observed against Delta. These results suggest that our assay can serve as a proxy for a much more involved virus neutralization assay against WT and VOC viruses.

Discussion

Our sensor complements previously described COVID-19 serological tests. First, our sensor does not require labeling of the RBD or variant RBDs, which makes it straightforward to substitute in new escape variant RBDs as they are identified. Previous studies have demonstrated detection of antibodies against the WT RBD; here, we demonstrate differentiation between antibodies based on their extent of reaction with WT and escape variant RBDs. Second, the components of the sensor can be readily made in *Escherichia coli* and can be lyophilized without loss of performance (Extended Data Figs. 9 and 10); hence, there are potential advantages in shelf life and manufacturing. The low stability of the ACE-2 protein has complicated high throughput, one-step serological detection of nAbs¹⁸, and use of the hyperstable LCB1 instead avoids this problem. A potential limitation of the lucCageRBD assay is that it detects only antibodies which bind at the ACE-2 binding site of the RBD and hence cannot quantify antibodies binding to other regions of spike or nucleocapsid¹⁹, but the RBD is a dominant target of nAbs, and hence, as confirmed by the strong correlation with neutralization titer over the human samples, this is not a substantial limitation. Further research will focus on incorporating the sensor into a scalable 384-well high-throughput format or a low-cost point-of-care diagnostic testing platform. More generally, with the recent advances of computational design to generate high-affinity binding proteins and protein switches, the approach described in this paper should be readily extensible to quantification of the binding affinity and abundance of a wide variety of analytes of interest.

Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41587-022-01280-8>.

Received: 3 June 2021; Accepted: 14 March 2022;
Published online: 28 April 2022

References

1. Korber, B. et al. Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus. *Cell* **182**, 812–827 (2020).

2. Seow, J. et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nat. Microbiol.* **5**, 1598–1607 (2020).
3. Chen, R. E. et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. *Nat. Med.* **27**, 717–726 (2021).
4. Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. *Cell* **184**, 2372–2383.e9 (2021).
5. Van Elslande, J. et al. Diagnostic performance of seven rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients. *Clin. Microbiol. Infect.* **26**, 1082–1087 (2020).
6. Nie, J. et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. *Emerg. Microbes Infect.* **9**, 680–686 (2020).
7. Whitman, J. D. et al. Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. *Nat. Biotechnol.* **38**, 1174–1183 (2020).
8. Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. *Nat. Biotechnol.* **38**, 1073–1078 (2020).
9. Quijano-Rubio, A. et al. De novo design of modular and tunable protein biosensors. *Nature* **591**, 482–487 (2021).
10. Cao, L. et al. De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. *Science* **370**, 426–431 (2020).
11. Yeh, H.-W. et al. Red-shifted luciferase-luciferin pairs for enhanced bioluminescence imaging. *Nat. Methods* **14**, 971–974 (2017).
12. Hurlburt, N. K. et al. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. *Nat. Commun.* **11**, 5413 (2020).
13. VanBlargan, L. A. et al. A potentially neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope. *Immunity* **54**, 2399–2416 (2021).
14. Liu, Z. et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. *Cell Host Microbe* **29**, 477–488 (2021).
15. ter Meulen, J. et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. *PLoS Med.* **3**, e237 (2006).
16. Wu, Y. et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. *Science* **368**, 1274–1278 (2020).
17. Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. *Cell* **183**, 1367–1382.e17 (2020).
18. Azad, T. et al. A high-throughput NanoBiT-based serological assay detects SARS-CoV-2 seroconversion. *Nanomaterials* **11**, 807 (2021).
19. McCallum, M. et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. *Cell* **184**, 2332–2347.e16 (2021).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022

Methods

Cells. HEK293T/17 is a human embryonic kidney cell line (ATCC, CRL-11268). The HEK-ACE2 adherent cell line was obtained through BEI Resources (NR-52511). All adherent cells were cultured at 37 °C with 8% CO₂ in flasks with Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Hyclone) and 1% penicillin-streptomycin (PenStrep).

HEK293F is a female human embryonic kidney cell line transformed and adapted to grow in suspension (Life Technologies). HEK293F cells were grown in 293FreeStyle expression medium (Life Technologies), cultured at 37 °C with 8% CO₂ and shaking at 130 rpm. Expi293F cells are derived from the HEK293F cell line (Life Technologies). Expi293F cells were grown in Expi293 Expression Medium (Life Technologies), cultured at 36.5 °C with 8% CO₂ and shaking at 150 rpm.

Vero E6 (CRL-1586, American Type Culture Collection), Vero-TMPRSS2 (a gift of S. Ding, Washington University) and Vero-hACE2-TMPRSS2 (a gift of A. Creanga and B. Graham, National Institutes of Health (NIH)) cells were cultured at 37 °C in DMEM supplemented with 10% FBS, 10 mM HEPES (pH 7.3), 1 mM sodium pyruvate, 1× nonessential amino acids and 100 U ml⁻¹ PenStrep. Vero-TMPRSS2 cell cultures were supplemented with 5 µg ml⁻¹ blasticidin. TMPRSS2 expression was confirmed using an anti-V5 antibody (Thermo Fisher Scientific, 2F11F7) or anti-TMPRSS2 mAb (Abnova, Clone 2F4) and APC-conjugated goat anti-mouse IgG (BioLegend, 405308). Vero-hACE2-TMPRSS2 cell cultures were supplemented with 10 µg ml⁻¹ puromycin.

mAbs. The murine mAbs SARS2-02 and SARS2-38 studied were isolated from BALB/c mice immunized with SARS-CoV-2 spike and RBD proteins and have been described previously¹⁷. Genes encoding CR3022, B38 and CV30 heavy and light chains were ordered from GenScript and cloned into pCMV/R. Antibodies were expressed by transient cotransfection of both heavy- and light-chain plasmids in Expi293F cells using PEI-MAX (Polyscience) transfection reagent. Cell supernatants were harvested and clarified after 3 or 6 days, and protein was purified using protein A chromatography (Cytiva). SPD-M162 was obtained from AcroBiosystems (AM122).

Live virus production. The 2019n-CoV/USA_WA1/2020 isolate of SARS-CoV-2 was obtained from the US Centers for Disease Control. The Alpha isolate was obtained from a nasopharyngeal sample after propagation on Vero-hACE2-TMPRSS2 cells¹. The chimeric WA1/2020 displaying Beta virus has been described previously³. All viruses were deep-sequenced and tittered on Vero-TMPRSS2 cells, and experiments were performed in an approved biosafety level 3 facility.

Pseudovirus production. Murine leukemia virus (MLV)-based and human immunodeficiency virus (HIV) SARS-CoV-2 S pseudotypes were prepared as previously described^{20,21}. Briefly for MLV, HEK293T cells were cotransfected using Lipofectamine 2000 (Life Technologies) with an S-encoding plasmid, an MLV Gag-Pol packaging construct and the MLV transfer vector encoding a luciferase reporter according to the manufacturer's instructions. For HIV, HEK293T cells were cotransfected using Lipofectamine 2000 (Life Technologies) with an S-encoding plasmid, an HIV Gag-Pol, Tat, Rev1B packaging construct and the HIV transfer vector encoding a luciferase reporter according to the manufacturer's instructions. Cells were washed three times with Opti-MEM before transfection and incubated for ~5 h at 37 °C with transfection medium. DMEM containing 10% FBS was added for ~60 h. The supernatants were harvested by spinning at 2,500 g, filtered through a 0.45-µm filter, concentrated with a 100-kDa membrane for 10 min at 2,500 g and then aliquoted and stored at -80 °C before use.

D614G SARS-CoV-2 S (YP 009724390.1), Alpha S, Beta S and Delta S pseudotypes VSVs were prepared as described previously²². Briefly, 293T cells in DMEM supplemented with 10% FBS, 1% PenStrep seeded in 10-cm dishes were transfected with the plasmid encoding for the corresponding S glycoprotein using Lipofectamine 2000 (Life Technologies) following the manufacturer's indications. One day after transfection, cells were infected with VSV(G*ΔG-luciferase) and after 2 h were washed five times with DMEM before adding medium supplemented with anti-VSV-G antibody (ATCC, I1- mouse hybridoma supernatant, CRL-2700). Virus pseudotypes were harvested 18–24 h after inoculation, clarified by centrifugation at 2,500 g for 5 min, filtered through a 0.45-µm cutoff membrane, concentrated 10 times with a 30-kDa cutoff membrane, aliquoted and stored at -80 °C.

Mouse serum. Female BALB/c (stock 000651) mice were purchased at the age of 4 weeks from The Jackson Laboratory and maintained at the Comparative Medicine Facility at the University of Washington (Seattle, WA), accredited by the American Association for the Accreditation of Laboratory Animal Care International. At 6 weeks of age, mice were immunized, and 3 weeks later, animals were boosted. Before inoculation, immunogen suspensions were gently mixed 1:1 vol/vol with AddaVax adjuvant (InvivoGen) to reach a final concentration of 0.009 or 0.05 mg ml⁻¹ antigen. Mice were injected intramuscularly into the gastrocnemius muscle of each hind leg using a 27-G needle (BD) with 50 µl per injection site (100 µl total) of immunogen under isoflurane anesthesia.

To obtain sera, all mice were bled 2 weeks after prime and boost immunizations. Blood was collected via submental venous puncture and rested in 1.5-ml plastic Eppendorf tubes at room temperature for 30 min to allow for coagulation. Serum was separated from hematocrit via centrifugation at 2,000 g for 10 min. Complement factors and pathogens in isolated serum were heat-inactivated via incubation at 56 °C for 60 min. Serum was stored at 4 °C or -80 °C until use. Mouse sera in this study were used in a previous study¹⁷.

Human serum and ELISA. Immune human sera/plasma specimens were from persons with documented SARS-CoV-2 infection in the United States between February and August 2020. Samples were obtained before vaccination or after vaccination with BNT162b2 or M1273 mRNA, after obtaining informed written consent in an institutional review board-approved protocol²³. Antibodies to the SARS-CoV-2 spike protein were measured using an ELISA specific for anti-S1 IgG (Euroimmun). Antibody levels were quantified by conversion of the optical density to a z-score relative to pre-pandemic serum anti-S1 IgG concentrations, as previously described²³. Sera tests were serial specimens obtained following immunization of laboratory volunteers in an institutional review board-compliant protocol. The negative samples (no SARS-CoV-2 nAbs) were serum samples collected for VZV research in 2016 and 2017, before SARS-CoV-2 was spreading in the United States.

General procedures for bacterial protein production and purification. The *E. coli* Lemo21(DE3) strain (New England Biolabs) was transformed with a pET29b⁺ plasmid encoding the synthesized gene of interest. Cells were grown for 24 h in LB medium supplemented with kanamycin. Cells were inoculated at a 1:50 ml ratio in the Studier TBM-5052 autoinduction medium supplemented with kanamycin, grown at 37 °C for 2–4 h and then grown at 18 °C for an additional 18 h. Cells were collected by centrifugation at 4,000 g at 4 °C for 15 min and resuspended in 30 ml lysis buffer (20 mM Tris-HCl, pH 8.0, 300 mM NaCl, 30 mM imidazole, 1 mM PMSF and 0.02 mg ml⁻¹ DNase). Cell resuspensions were lysed by sonication for 2.5 min (5 s cycles). Lysates were clarified by centrifugation at 24,000 g at 4 °C for 20 min and passed through 2-ml Ni-NTA nickel resin (Qiagen, 30250) pre-equilibrated with wash buffer (20 mM Tris-HCl, pH 8.0, 300 mM NaCl and 30 mM imidazole). The resin was washed twice with 10 column volumes (CVs) of wash buffer, and then eluted with 3 CVs elution buffer (20 mM Tris-HCl, pH 8.0, 300 mM NaCl and 300 mM imidazole). The eluted proteins were concentrated using Ultra-15 Centrifugal Filter Units (Amicon) and further purified by using a Superdex 75 Increase 10/300 GL (GE Healthcare) size exclusion column in TBS (25 mM Tris-HCl, pH 8.0, and 150 mM NaCl). Fractions containing monomeric protein were pooled, concentrated and snap-frozen in liquid nitrogen and stored at -80 °C.

Plasmid construction for RBD. The SARS-CoV-2 RBD (UniProt: P0DTC2) (BEI NR-52422), Alpha (N501Y), Beta (K417N, E484K and N501Y) and Delta (L452R and T478K) constructs were synthesized by GenScript into pCDNA3.1- or CMV with an N-terminal mu-phosphatase signal peptide and a C-terminal octa-histidine tag (GHHHHHHHH). The boundaries of the construct are N-328RFPN331 and 528KKST531-C (ref. ¹⁷).

Transient transfection. RBD proteins were produced in Expi293F cells grown in suspension using Expi293F expression medium (Life Technologies) at 33 °C, 70% humidity, 8% CO₂ rotating at 150 rpm. The cultures were transfected using PEI-MAX (Polyscience) with cells grown to a density of 3.0 million cells per milliliter and cultivated for 3 days. Supernatants were clarified by centrifugation (5 min at 4,000 rcf), addition of polydiallyldimethylammonium chloride solution to a final concentration of 0.0375% (Sigma Aldrich, 409014) and a second spin (5 min at 4,000 rcf).

Purification of RBD. His-tagged RBD was purified from clarified supernatants via a batch bind method, where each clarified supernatant was supplemented with 1 M Tris-HCl, pH 8.0, to a final concentration of 45 mM and 5 M NaCl to a final concentration of 310 mM. Talon cobalt affinity resin (Takara Bio) was added to the treated supernatants and allowed to incubate for 15 min with gentle shaking. Resin was collected using vacuum filtration with a 0.2-µm filter and transferred to a gravity column. The resin was washed with 20 mM Tris, pH 8.0, 300 mM NaCl, and the protein was eluted with 3 CVs of 20 mM Tris, pH 8.0, 300 mM NaCl and 300 mM imidazole. The batch bind process was then repeated and the first and second elutions combined. SDS-PAGE was used to assess purity. Following immobilized metal affinity chromatography purification, the elution was concentrated and applied to a Cytiva S200 Increase column equilibrated with 20 mM Tris 150 mM NaCl, pH 8.0, and the peak of interest was collected and quantified using A280. The purified RBD was qualified using BLI to confirm binding using CR3022 and hACE2-Fc.

In vitro bioluminescence characterization with mAbs. A Synergy Neo2 Microplate Reader (BioTek) was used for all in vitro bioluminescence measurements. Assays were performed in 50% HBS-EP (GE Healthcare Life Sciences) plus 50% Nano-Glo assay buffer. For each well of a white opaque 96-well plate, 5 µl of 10× lucCage, 5 µl of 10× lucKey, 5 µl of 10× RBD and 5 µl of 10×

antibody and remaining volume of buffer for in total 50 μl were mixed to reach the indicated concentration and ratio. The lucCage and lucKey components were incubated for 30 min at room temperature to enable pre-equilibration. The plate was centrifuged at 1,000 g for 10 s and incubated at room temperature for a further 30 min. Then, 15 μl of 100 \times diluted furimazine (Promega, Nano-Glo luciferase assay reagent) was added to each well. Bioluminescence measurements in the absence of target were taken every 1 min (0.1 s integration and 10 s shaking during intervals) for a total of 30 min. To calculate the percent decrease in dynamic range for the graphs, the following formula was used:

$$\text{Fraction of lucCageRBD dynamic range lost} = 1 - \frac{L_x - L_{\min}}{L_{\max} - L_{\min}},$$

where L_x is the luminosity with 5 nM RBD and the tested antibody concentration, L_{\min} is the luminosity when no RBD is added, and L_{\max} is the luminosity when only 5 nM RBD is added. To derive EC_{50} values from the bioluminescence-to-analyte plot, the top three peak bioluminescence intensities at individual analyte concentrations were averaged, subtracted from blank and used to fit the sigmoidal 4PL curve.

Detection of spiked RBD in human serum specimens. Serum specimens were derived from excess plasma or sera from adults (>18 years) of both genders provided by the Director of the Clinical Chemistry Division, the hospital of University Washington. Serum specimens were obtained in compliance with approval by the University of Washington Human Subjects Division. All anonymized donor specimens were provided deidentified. Because the donors consented to have their excess specimens be used for other experimental studies, they could be transferred to our study without additional consent. All samples were passed through 0.22- μm filters before use, and 5 μl of 10 \times monomeric RBD (10 or 1,000 nM), 5 μl of 10 \times lucCage (10 nM), 5 μl of 10 \times lucKey (10 nM), 5 μl of 10 \times Antares2 (0.5 nM) and the indicated amount of human donor serum or simulated nasal matrix were mixed with 1:1 HBS/Nano-Glo assay buffer to reach a total volume of 50 μl . The plate was centrifuged at 1,000 g for 10 s. After 30-min incubation, 15 μl of 100 \times diluted furimazine in buffer was added to each well. Bioluminescence signals were recorded from both 470/40-nm and 590/35-nm channels every 1 min for a total of 30 min. The ratio (R) at each time point was calculated by the following equation as previously described¹¹:

$$R = \frac{T_{470 \text{ nm}} - T_{590 \text{ nm}} \times 0.43}{T_{590 \text{ nm}}},$$

where $T_{470 \text{ nm}}$ and $T_{590 \text{ nm}}$ are the total luminescent signals at 470 nm and 590 nm, respectively. For calculating the fraction of lucCageRBD dynamic range lost for serum samples in Extended Data Fig. 6, the following equation was used:

$$\text{Fraction of lucCageRBD dynamic range lost} = 1 - \frac{R_x - R_{\min}}{R_{\max} - R_{\min}},$$

where R_x is the R with 1 nM RBD in serum sample, R_{\min} is the R of serum sample but no RBD, and R_{\max} is the R of 100 nM RBD in the same serum sample.

To assay 64 serum samples in Fig. 2 and Extended Data Fig. 8 (including 40 from either convalescent or vaccinated patients and 24 pre-2019 donors), 5 μl primer diluted serum sample and 5 μl of 10 nM RBD (WT or Delta) were pre-mixed in DPBS for 20 min at room temperature. A 15- μl mixture containing 5 μl lucCageRBD (10 nM), 5 μl lucKey (10 nM) and 5 μl Antares2 (0.2 nM) was subsequently added to each well and incubated for another 10 min; 25 μl furimazine substrate (200 \times dilution) was added to each well, and luminescence signals were acquired immediately by Neo2 plate reader at 470/40-nm and 590/35-nm channels for a total of 20 min (1-min interval and 0.1-s exposure, and instrumental gain values were set to 120 at the 470-nm channel and 145 at the 590-nm channel). The final assay concentration contains 1 nM lucCageRBD, 1 nM lucKey, 20 pM Antares2 and 1 nM RBD. The person performing the lucCageRBD assays was blinded as to the serum samples being tested, and another person analyzed the assay data. For calculating the fraction of lucCageRBD dynamic range lost for serum samples in Fig. 2 and Extended Data Fig. 8, the following equation was used:

$$\text{Fractional decrease in lucCageRBD signal} = 1 - \frac{R_x - R_{\min}}{R_{\min}}.$$

To simplify the calculation, R_x here is reported as the ratio of the total luminescent signal at 470 nm over 590 nm ($T_{470 \text{ nm}}/T_{590 \text{ nm}}$) with 1 nM RBD in serum sample and R_{\min} is the ratio of serum sample without the addition of RBD. Ten steady-state ratio values were averaged and assigned as R_x of the corresponding sample. R_{\max} was omitted herein because R_{\max} was unreliable with some samples due to high nAb titer.

In vitro bioluminescence characterization of lyophilized biosensors. Five microliters of 10 \times lucCage and 5 μl of 10 \times lucKey were added to each well of a white opaque 96-well plate and lyophilized overnight. The biosensor was reconstituted in 10 μl dH₂O before testing, and then 84 μl of 50% HBS-EP (GE Healthcare Life Sciences) plus 50% Nano-Glo assay buffer was added to each

well. The lucCage and lucKey components were incubated for 30 min at room temperature to enable pre-equilibration. One microliter of 100 \times diluted furimazine was added to each well. The plate was centrifuged at 1,000 g for 10 s. Then, 5 μl serially diluted target RBD was added to each well and measured in a Synergy Neo2 Microplate Reader. Measurements were taken every 1 min (0.1-s integration and 10-s shaking during intervals) for a total of 90 min.

BLI. Protein-protein interactions were measured by using an Octet RED96 System (ForteBio) using streptavidin-coated biosensors (ForteBio). Each well contained 200 μl solution, and the assay buffer was HBS-EP + buffer (GE Healthcare Life Sciences, 10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% (v/v) surfactant P20) plus 0.5% non-fat dry milk blotting grade blocker (Bio-Rad). The biosensor tips were loaded with analyte peptide or protein at 20 $\mu\text{g ml}^{-1}$ for 300 s (threshold of 0.8-nm response), incubated in HBS-EP + buffer for 60 s to acquire the baseline measurement, dipped into the solution containing cage and/or key for 1,800 s (association step) and dipped into the HBS-EP + buffer for 1,800 s (dissociation steps). The binding data were analyzed with the ForteBio Data Analysis Software version 9.0.0.10.

Live and pseudovirus entry and serum neutralization assays. SARS-02 and SARS2-38 were assayed for neutralization potency by focus-reduction neutralization test as described previously²⁴ and using Vero-TMPRSS2 cells. Briefly, serial dilutions of antibody were incubated with 2×10^2 focus-forming units of SARS-CoV-2 of the indicated strain for 1 h at 37 $^{\circ}\text{C}$ in duplicate. Immune complexes were then added to Vero-TMPRSS2 cell monolayers in a 96-well plate and incubated for 1 h at 37 $^{\circ}\text{C}$ before the addition of 1% (w/v) methylcellulose in MEM. Following incubation for 30 h at 37 $^{\circ}\text{C}$, cells were fixed with 4% paraformaldehyde, permeabilized and stained for infection foci with a mixture of mAbs that bind various epitopes on the RBD and NTD of spike (SARS2-02 and SARS2-38; diluted to 1 $\mu\text{g ml}^{-1}$ total mAb concentration). Antibody-dose response curves were analyzed using nonlinear regression analysis (with a variable slope) (GraphPad Software).

For the mAbs CV30, B38 and CR3022 and for the vaccinated human serum samples with pseudovirus, HEK-hACE2 cells were cultured in DMEM with 10% FBS (Hyclone) and 1% PenStrep with 8% CO₂ in a 37 $^{\circ}\text{C}$ incubator (Thermo Fisher Scientific). Before plating, 40 μl poly-L-lysine (Sigma) was placed into 96-well plates and incubated with rotation for 5 min. Poly-L-lysine was removed, plates were dried for 5 min then washed 1 \times with water before plating 2×10^4 cells. The following day, cells were checked to be at 80% confluence. In a half-area 96-well plate a 1:3 serial dilution of mAb or sera was made in DMEM in 22 μl final volume. 22 μl pseudovirus was then added to the serial dilution and incubated at room temperature for 30–60 min. HEK-hACE2 plate media was removed and 40 μl of the sera/virus mixture was added to the cells and incubated for 2 h at 37 $^{\circ}\text{C}$ with 8% CO₂. Following incubation, 40 μl 20% FBS and 2% PenStrep containing DMEM was added to the cells for 24–48 h. Following the infection, One-Glo-EX (Promega) was added to the cells in half culturing volume (40 μl added) and incubated in the dark for 5 min before reading on a BioTek plate reader. Measurements were done on all mAbs and human serum samples from each group in at least duplicate. Relative luciferase units were plotted and normalized in Prism (GraphPad) using a zero value of cells alone and a 100% value of 1:2 virus alone. Nonlinear regression of log(inhibitor) versus normalized response was used to determine IC₅₀ values from curve fits.

Sensor simulations. Mathematical models describing the ternary and quaternary sensor systems were simulated to test their responses to changes in their input parameters (concentrations and affinities of intervening species). Systems of ordinary differential equations describing the kinetics of the interactions between the species involved in each sensor were numerically integrated using integrate.odeint() as implemented in Scipy (version 1.6.3) (ref. ²⁵). Steady-state values were used to determine the distribution of species at thermodynamic equilibrium.

The ternary system is composed of the following species: ACE-2, RBD, nAb, ACE-2:RBD and RBD:nAb. The following set of equations was used to describe the system:

$$\frac{d[\text{ACE2}]}{dt} = -k_1 [\text{ACE2}] [\text{RBD}] + k_{-1} [\text{ACE2} : \text{RBD}]$$

$$\frac{d[\text{RBD}]}{dt} = -k_1 [\text{ACE2}] [\text{RBD}] + k_{-1} [\text{ACE2} : \text{RBD}] - k_2 [\text{RBD}] [\text{nAb}] + k_{-2} [\text{RBD} : \text{nAb}]$$

$$\frac{d[\text{nAb}]}{dt} = -k_2 [\text{RBD}] [\text{nAb}] + k_{-2} [\text{RBD} : \text{nAb}]$$

$$\frac{d[\text{ACE2} : \text{RBD}]}{dt} = k_1 [\text{ACE2}] [\text{RBD}] - k_{-1} [\text{ACE2} : \text{RBD}]$$

$$\frac{d[\text{RBD} : \text{nAb}]}{dt} = k_2 [\text{RBD}] [\text{nAb}] - k_{-2} [\text{RBD} : \text{nAb}],$$

where k_i describe bimolecular association rate constants and k_{-i} represent unimolecular dissociation rate constants. $K_1 = k_{-1}/k_1$ and $K_2 = k_{-2}/k_2$ describe the equilibrium dissociation constants for the ACE-2:RBD and RBD:nAb complexes, respectively. For all ternary system simulations, K_1 was set to 15 nM (ref. 26). For consistency with the metric used to report on the quaternary system response (fraction of lucCageRBD dynamic range lost; described in section 'In vitro bioluminescence characterization with monoclonal antibodies'), simulations for the ternary system were reported as:

$$\text{Fraction sensor dynamic range lost} = 1 - L_x/L_{\max},$$

where L_x is the signal observed when all three species are present, and L_{\max} is the response when nAb is absent.

The quaternary system is composed of the following species: closed state of the Cage-Latch, open state of the Cage-Latch (oCL), lucKey, RBD, nAb, lucKey:oCL, oCL:RBD, lucKey:oCL:RBD and RBD:nAb. Only the oCL is considered binding-competent, whereas the closed state of the Cage-Latch is not. The following set of equations was used to describe the system:

$$\frac{d[\text{oCL}]}{dt} = -k[\text{oCL}] + k_{-1}[\text{lucKey} \cdot \text{oCL}]$$

$$\frac{d[\text{lucKey} \cdot \text{oCL}]}{dt} = k[\text{oCL}] - k_{-1}[\text{lucKey} \cdot \text{oCL}] - k_1[\text{lucKey}] [\text{oCL}] + k_{-1}[\text{lucKey} \cdot \text{oCL}] - k_2[\text{oCL}] [\text{RBD}] + k_{-2}[\text{oCL} \cdot \text{RBD}]$$

$$\frac{d[\text{lucKey}]}{dt} = -k_1[\text{lucKey}] [\text{oCL}] + k_{-1}[\text{lucKey} \cdot \text{oCL}] - k_1[\text{lucKey}] [\text{oCL} \cdot \text{RBD}] + k_{-1}[\text{lucKey} \cdot \text{oCL} \cdot \text{RBD}]$$

$$\frac{d[\text{RBD}]}{dt} = -k_2[\text{oCL}] [\text{RBD}] + k_{-2}[\text{oCL} \cdot \text{RBD}] - k_2[\text{lucKey} \cdot \text{oCL}] [\text{RBD}] + k_{-2}[\text{lucKey} \cdot \text{oCL} \cdot \text{RBD}] - k_3[\text{RBD}] [\text{nAb}] + k_{-3}[\text{RBD} \cdot \text{nAb}]$$

$$\frac{d[\text{nAb}]}{dt} = -k_3[\text{RBD}] [\text{nAb}] + k_{-3}[\text{RBD} \cdot \text{nAb}]$$

$$\frac{d[\text{lucKey} \cdot \text{oCL}]}{dt} = k_1[\text{lucKey}] [\text{oCL}] - k_{-1}[\text{lucKey} \cdot \text{oCL}] - k_2[\text{lucKey} \cdot \text{oCL}] [\text{RBD}] + k_{-2}[\text{lucKey} \cdot \text{oCL} \cdot \text{RBD}]$$

$$\frac{d[\text{oCL} \cdot \text{RBD}]}{dt} = k_2[\text{oCL}] [\text{RBD}] - k_{-2}[\text{oCL} \cdot \text{RBD}] - k_1[\text{lucKey}] [\text{oCL} \cdot \text{RBD}] + k_{-1}[\text{lucKey} \cdot \text{oCL} \cdot \text{RBD}]$$

$$\frac{d[\text{lucKey} \cdot \text{oCL} \cdot \text{RBD}]}{dt} = k_1[\text{lucKey}] [\text{oCL} \cdot \text{RBD}] - k_{-1}[\text{lucKey} \cdot \text{oCL} \cdot \text{RBD}] + k_2[\text{lucKey} \cdot \text{oCL}] [\text{RBD}] - k_{-2}[\text{lucKey} \cdot \text{oCL} \cdot \text{RBD}]$$

$$\frac{d[\text{RBD} \cdot \text{nAb}]}{dt} = k_3[\text{RBD}] [\text{nAb}] - k_{-3}[\text{RBD} \cdot \text{nAb}],$$

where k_i describes the bimolecular association rate constant and k_{-i} represents the unimolecular dissociation rate constant. $K_1 = k_{-1}/k_1$, $K_2 = k_{-2}/k_2$ and $K_3 = k_{-3}/k_3$ describe the affinities (equilibrium dissociation constants) for the binding interfaces lucKey:oCL, oCL:RBD and RBD:nAb, respectively. The binding of lucKey and RBD to the open Cage-Latch species is considered symmetrical (i.e., noncooperative), meaning that the binding events are independent. $K = k_{-1}/k_1 = \exp(\Delta G_{\text{open}}/RT)$ describes the unimolecular binding equilibrium of the Latch to the Cage, with ΔG_{open} the free energy of Latch opening, R the universal gas constant and T the thermodynamic temperature (set to 298.15 K for all simulations).

These systems were simulated over a range of species concentrations, as well as RBD:nAb affinities, to explore the behavior of each sensor, and gain insights into the influence of different variables on the position of the detection thresholds. The python code for running these simulations is provided as a Jupyter notebook: https://github.com/bwicky/covid_nAb_sensor_simulation.

Statistical analysis. No statistical methods were used to predetermine the sample size. No sample was excluded from data analysis, and no blinding was used. Deidentified clinical serum samples were randomly used for spiking in target proteins. Results were successfully reproduced using different batches of pure proteins on different days. Unless otherwise indicated, data are shown

as mean \pm s.e.m., and error bars in figures represent s.e.m. of technical triplicates. BLI data were analyzed using ForteBio Data Analysis Software version 9.0.0.10. All data were analyzed and plotted using GraphPad Prism 8.

Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request. All accession codes have been provided for the paper. Source data are provided with this paper.

Code availability

The code for the sensor simulations is made available as an interactive Jupyter notebook at https://github.com/bwicky/covid_nAb_sensor_simulation. Source data are provided with this paper.

References

- Millet, J. K. & Whittaker, G. R. Murine leukemia virus (MLV)-based coronavirus Spike-pseudotyped particle production and infection. *Bio. Protoc.* **6**, e2035 (2016).
- Crawford, K. H. D. et al. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. *Viruses* **12**, 513 (2020).
- Sauer, M. M. et al. Structural basis for broad coronavirus neutralization. Preprint at *bioRxiv* <https://doi.org/10.1101/2020.12.29.424482> (2021).
- Boonyaratankornkit, J. et al. Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates. *J. Clin. Invest.* **131**, e144930 (2021).
- Case, J. B., Bailey, A. L., Kim, A. S., Chen, R. E. & Diamond, M. S. Growth, detection, quantification, and inactivation of SARS-CoV-2. *Virology* **548**, 39–48 (2020).
- Virtanen, P. et al. SciPy 1.0: fundamental algorithms for scientific computing in Python. *Nat. Methods* **17**, 261–272 (2020).
- Glasgow, A. et al. Engineered ACE2 receptor traps potentially neutralize SARS-CoV-2. *Proc. Natl. Acad. Sci. U S A* **117**, 28046–28055 (2020).

Acknowledgements

This work was supported in part through the Henrietta and Aubrey Davis Endowed Professorship in the UW Department of Biochemistry (D.B.), National Institutes of Health grant U01 AI151698 for the United World Antiviral Research Network (UWARN) (D.B., L.S., H.-W.Y. and J.Z.Z.), the Audacious Project at the Institute for Protein Design (D.B., H.-W.Y. and W.Y.), Eric and Wendy Schmidt by recommendation of the Schmidt Futures (H.-W.Y. and A.Q.-R.), The Open Philanthropy Project Improving Protein Design Fund (D.B. and S.E.B.), the Bill & Melinda Gates Foundation (OPP1156262 D.V.), the European Molecular Biology Organization (fellowship ALTF 139-2018 to B.I.M.W.), Gree Real Estate (D.B.), the National Institute of General Medical Sciences (R01GM120553 to D.V.), the National Institute of Allergy and Infectious Diseases (DPIA1158186 and HHSN272201700059C to D.V.), a Pew Biomedical Scholars Award (D.V.), Investigators in the Pathogenesis of Infectious Disease Awards from the Burroughs Wellcome Fund (D.V.) and Fast Grants (D.V.), National Institute of Allergy and Infectious Diseases contract 75N93019C00063 (D.M.K.). This study also was supported by National Institutes of Health grant R01 AI157155 (M.S.D.). We thank Hideki Tani (University of Toyama) for providing the reagents necessary for preparing VSV pseudotyped viruses. We also thank Robert Waterson and Wesley C. Van Voorhis for advice and support with the anti-SARS-CoV-2 antibody sensors, B. Fiala at the Institute for Protein Design for providing SARS-CoV-2 RBD and LCB1, S. Selke for data management of convalescent/vaccinated human serum/plasma samples and A. Wald for coordinating the clinical protocols allowing specimen collection at the Virology Research Clinic, Harborview Medical Center, University of Washington.

Author contributions

D.B. conceived and supervised the project. J.Z.Z. and H.-W.Y. designed the research and performed all biosensor assays. D.V. supervised and A.C.W. and K.S. performed pseudovirus neutralization assays. B.I.M.W. created the thermodynamic equilibrium simulations of sensor systems. J.Z.Z. and H.-W.Y. analyzed lucCageRBD and BLI data. L.A.V. and M.S.D. provided SARS2-02 and SARS2-38 antibodies and performed live virus neutralization experiments. R.T., M.W., A.L.G. and D.M.K. provided convalescent and/or vaccinated and negative control human serum samples and performed ELISAs. M.N.P. and J.C.K. provided vaccinated mouse serum samples and performed ELISAs. A.Q.-R. performed lyophilization experiments. M.D., J.E.B., C.C., R.R. and L.C. performed production and purification of proteins. J.Z.Z., H.-W.Y., B.I.M.W., L.S. and D.B. wrote the original draft. All authors reviewed and commented on the manuscript.

Competing interests

D.B., A.Q.-R., H.-W.Y. and L.S. are co-inventors in a provisional patent application (PCT/US2021/034104) covering the SARS-CoV-2 RBD biosensor described in this

article. M.S.D. is a consultant for Inbios, Vir Biotechnology and Fortress Biotech and on the Scientific Advisory Boards of Moderna and Immunome. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Moderna, Vir Biotechnology and Emergent BioSolutions. The Veessler laboratory has received unrelated funding support in sponsored research agreement from Vir Biotechnology.

Additional information


Extended data is available for this paper at <https://doi.org/10.1038/s41587-022-01280-8>.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41587-022-01280-8>.

Correspondence and requests for materials should be addressed to Jason Z. Zhang or David Baker.


Peer review information *Nature Biotechnology* thanks Mirko Trilling and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at www.nature.com/reprints.




Extended Data Fig. 1 | See next page for caption.


Extended Data Fig. 1 | Simulation of biosensor systems and experimental validation. **a**, Schematic of the LOCKR nAb biosensor system (quaternary, this work), and **b**, ACE-2:RBD out-competition format (ternary, previous work). These schematics are the same as in Fig. 1. **c-d**, Simulations of detection capabilities as a function of sensor settings (concentration of sensor components) along the dimension of each independent variable. The decision boundaries (EC50) are shown as solid lines. **c**, The concentration of RBD primarily affects the antibody titer detection limit. For tight antibodies (right-hand side of the plots), the position of the decision boundary (EC50) is solely determined by the concentration of RBD. The concentrations of the untitrated components were: Cage-Latch = 1 nM, lucKey = 50 nM for the quaternary system, and ACE-2 = 1 nM for the ternary system. **d**, Effect of ACE-2 or lucKey concentrations on the ternary and quaternary sensors respectively. Changing lucKey concentration in the quaternary case allows for a better modulation of the nAb affinity detection threshold. The concentration of RBD was set to 50 nM in both cases, and the concentration of Cage-Latch was set to 1 nM for the quaternary system. **e,f**, Simulations of outputs for decision matrices of the quaternary (**e**), or ternary (**f**) sensors. Each matrix represents the simulated responses for 16 different sensor settings (concentrations of sensor species, indicated at the bottom-right) to a given concentration of nAb of a specific affinity. The quaternary system is capable of deconvoluting affinity and concentration across all combinations that activate the sensor (distinct patterns), while the ternary system returns the same reading for the cases where nAb affinity and concentrations are in the same range (diagonal, highlighted by dashed squares). **g**, Diagonal of decision matrices for ternary systems composed of RBD and LCB1 instead of ACE-2. Sensor readings using the same concentrations of species as the ACE-2:RBD system (top) or adjusted concentrations (bottom). **h**, Simulated maximum raw signals for the ternary system sensor as in (**g**) with unmodified settings (left), and adjusted concentrations (right). The unmodified settings reduce the raw maximum signal range, but also reduce the detection capabilities of the sensor. Adjusting the settings to improve detection also increases the raw maximum signal range. **i-j**, Comparison between simulated and experimental data. **i**, Different concentrations of either CV30 (high affinity; $K_d = 25$ nM) or B38 (low affinity; $K_d = 192$ nM) mAbs with 1 nM RBD sensor and different concentrations of WT RBD and lucKey in the lucCageRBD assay (experimental and simulation data, top and bottom respectively). **j**, Heat map representation summarizing some of the experimental data from (**i**) for low and high concentrations of CV30 and B38 antibodies (simulation and experimental data, top and bottom respectively). All lucCageRBD experiments were performed in triplicate, representative data are shown, and data are mean \pm s.e.m. The quaternary system was simulated with the following parameters: $\Delta G_{open} = 4$ kcal/mol, $[Cage - Latch] = 1$ nM, $K(lucKey : oCL) = 5$ nM, $K(oCL : RBD) = 500$ pM. The ternary system was simulated with $K(ACE2 : RBD) = 15$ nM, except for **g-h**, where $K(LCB1 : RBD) = 500$ pM was used instead. Cases where simulations did not converge are shown as white squares.




Extended Data Fig. 2 | Reversibility of lucCageRBD. Time-course luminescence of the lucCageRBD assay using 200 nM of RBD WT and different concentrations of the *de novo* LCB1.1 binder. All experiments were performed in triplicate, representative data are shown.




Extended Data Fig. 3 | Detection of RBD strains by lucCageRBD. a-d, Fold change increase in luminescence from different concentrations of RBD WT (**a**), Alpha (**b**), Beta (**c**), Delta (**d**) tested in the lucCageRBD assay. All experiments were performed in triplicates and data are mean \pm s.e.m.




Extended Data Fig. 4 | Effects of RBD and sensor titration on detecting SARS-CoV-2 antibodies. a,b, Resulting fraction of lucCageRBD dynamic range lost (**a**) and lucCageRBD EC50 (**b**) from different concentrations of mAb CV30 with different concentrations of RBD WT in 1 nM of RBD sensor and lucKey. **c-d,** Resulting fraction of lucCageRBD dynamic range lost (**c**) and lucCageRBD EC50 (**d**) from different concentrations of mAb CV30 with different concentrations of RBD sensor and lucKey (1:1 stoichiometry maintained) and with 5 nM RBD. All experiments were performed in triplicates and data are mean \pm s.e.m.



Extended Data Fig. 5 | Monoclonal antibodies tested for lucCageRBD, binding, and neutralization. **a–f**, Different concentrations of either CV30 (**a–c**) or B38 (**e–g**) mAbs with 5 nM RBD WT, Alpha, and Beta were tested in the lucCageRBD assay (**a, d**), BLI for binding to RBD strains (**b, e**), and spike VoC-presenting pseudovirus infection (VSV-based for **c**, HIV-based for **f**). Comparison of lucCageRBD EC₅₀ and neutralization IC₅₀ plotted linear-linear (left) or log-log (right) (**g**), binding affinity (k_d) and neutralization IC₅₀ (**h**), and lucCageRBD EC₅₀ and k_d (**i**). All lucCageRBD and BLI experiments were performed in triplicate, neutralization experiments were performed in at least duplicate and data are mean \pm s.e.m.




Extended Data Fig. 6 | Detection of neutralizing antibodies in vaccinated serum. **a,b**, Serum (10%) from vaccinated mice were collected and tested for pseudovirus infection (**a**), in ELISA (\log_{10} reciprocal EC50 titer) (**b**), and in the lucCageRBD assay (**a, b**) ($n=12$ serum samples). (Inset) Mouse serum samples pre-immunization, post-prime dosing (week 3), and post-boost dosing (week 5) were collected and tested in the lucCageRBD assay. **c-d**, Serum (10%) from vaccinated patients were tested for pseudovirus infection (**c**), in ELISA (\log_{10} reciprocal EC50 titer) (**d**), and in the lucCageRBD assay (**c, d**) using RBD WT, Alpha, and Beta ($n=12$ serum samples). **e-f**, Serum collected from patients pre and post vaccination were tested in the Eurolmmun ELISA for anti-spike antibodies. Patient's anti-spike antibody levels (measured by Z-score) were measured several days after vaccination. Z-score is plotted either in linear (**e**) or \log_{10} scale (**f**). All neutralization experiments were performed in at least duplicates, all lucCageRBD and ELISA experiments were performed in triplicate and data are mean \pm s.e.m.




Extended Data Fig. 7 | See next page for caption.


Extended Data Fig. 7 | Pseudovirus neutralization curves for clinical samples. a,b, (a) Serum from convalescent and/or vaccinated patients and pre-2019 serum samples **(b)** were collected and tested for pseudovirus infection against Delta spike. **c, IC50** values of serum from convalescent and/or vaccinated patients (blue) or pre-2019 serum samples (red) for blocking Delta-spike containing pseudoviral entry. Bar graph is plotted either linearly (top) or logarithmically (bottom).



Extended Data Fig. 8 | Detection of neutralizing antibodies in clinical samples. **a**, Serum from convalescent and/or vaccinated patients (positive samples, $n=40$) and pre-2019 samples (negative samples, $n=24$) were collected and tested in both the lucCageRBD and ELISA assay and pseudovirus infection against WT RBD. **b**, The same samples were tested for neutralization of either WT or Delta spike-presenting pseudovirus with log₁₀ IC₅₀ neutralization reported. Viral infection experiments were performed in duplicate, and data are mean \pm s.e.m. r represents Pearson's coefficient. ** $P=0.0012$, two-tailed student's t -test.



Extended Data Fig. 9 | Production and purification of recombinant proteins used in LOCKR biosensor for serological diagnosis of neutralizing antibodies. **a**, Individual His₆ tagged versions of lucKey (27.4 KDa) and lucCageRBD (47.8 KDa) are expressed in *E. coli* and following cell lysis are purified by IMAC using 50 mM imidazole in buffer elution. **b**, His₆ tagged SARS-CoV-2 RBD (30 KDa) is expressed as a secreted protein in human 293 cells transiently transfected with DNA vectors encoding the protein which is purified from serum free culture medium by IMAC using 50 mM imidazole in buffer elution. **c**, His₆ tagged LCB1 anti-SARS-CoV-2 RBD minibinder (7 KDa) is expressed in *E. coli* (whole cell). Following cell lysis by heating to 95 °C and centrifugation to separate insoluble from soluble material, the LCB1 minibinder protein is >90% pure. Samples shown in A-C were analyzed by SDS-PAGE with reducing agent and Coomassie blue staining (molecular weight standards shown). All experiments were performed in triplicate, representative data are shown.



Extended Data Fig. 10 | lucCageRBD biosensor sensitivity before and after lyophilization. lucCageRBD and lucKey were lyophilized at 10X concentration in a 96-well plate. After reconstitution in liquid format, the biosensor was tested at a final concentration of 1 nM lucCageRBD and 1 nM lucKey for the detection of serially diluted RBD. All experiments were performed in triplicates and data are mean \pm s.e.m.

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection Bioluminescence data acquired on Synergy Neo2 multi-mode microplate reader (Biotek). Biolayer interferometry data acquired on Octet RED96 (ForteBio).

Data analysis Bioluminescence data were analyzed and plotted using GraphPad Prism 8. Target response curves were fitted using a Sigmoidal 4PL fit in GraphPad Prism 8. BLI data was analyzed using ForteBio Data Analysis Software version 9.0.0.10 and plotted using GraphPad Prism 8. The code for the numerical simulations shown in this manuscript uses Scipy 1.6.3 and are available as an interactive Jupyter notebook at https://github.com/bwicky/covid_nAb_sensor_simulation.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request. All accession codes have been provided for the paper. Source data are provided with this paper. Computational source data is uploaded onto https://github.com/bwicky/covid_nAb_sensor_simulation.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	We measured 40 SARS-CoV-2 patient samples and 30 control samples. The sample size is chosen based on the availability of patient samples and is sufficient for statistical analysis for calculating assay specificity and sensitivity.
Data exclusions	No sample was excluded from data analysis.
Replication	The results were successfully replicated using different batches of pure proteins on different days. All samples were measured at least twice and replications were successful.
Randomization	This is not relevant as this paper is an observational study, which does not involve treatment and will not be affected by relevant bias.
Blinding	Clinical samples were given with numbers that do not correlate to the characteristics of the sample. Both samples and controls were measured in the same plates under same conditions. Data was first processed in blinded mode, followed by sample/control assignment.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Antibodies

Antibodies used

1. SARS-CoV-2 antibodies SARS2-02 (produced by Diamond lab)
2. SARS-CoV-2 antibodies SARS2-38 (produced by Diamond lab)
3. SARS-CoV antibody CR3022 (produced by Baker lab)
4. SARS-CoV-2 antibodies B38 (produced by Baker lab)
5. SARS-CoV-2 antibodies CV30 (produced by Baker lab)
6. anti-V5 antibody (Thermo Fisher Scientific, 2F11F7) (dilution 1:1000)
7. anti-TMPRSS2 mAb (Abnova, Clone 2F4) (dilution 1:1000)
8. APC-conjugated goat anti-mouse IgG (BioLegend, 405308) (dilution 1:5000)

Validation

1. Validation of SARS-CoV-2 antibody SARS2-02 is described here: Liu, Z. et al. Cell Host Microbe 2021. This antibody is a murine monoclonal antibody isolated from BALB/c mice immunized with SARS-CoV-2 spike and RBD proteins. This antibody was validated to bind to the receptor binding domain of SARS-CoV-2 spike protein based on biolayer interferometry data in this work.
2. Validation of SARS-CoV-2 antibody SARS2-38 is described here: Liu, Z. et al. Cell Host Microbe 2021. This antibody is a murine monoclonal antibody isolated from BALB/c mice immunized with SARS-CoV-2 spike and RBD proteins. This antibody was validated to bind to the receptor binding domain of SARS-CoV-2 spike protein based on biolayer interferometry data in this work.
3. Validation of SARS-CoV antibody CR3022 is described here: ter Meulen, J. et al. PLoS Med 2006. Genes encoding this antibody were ordered from GenScript and cloned into pCMV/R. Antibodies were expressed by transient co-transfection of both heavy and light chain plasmids in Expi293F cells using PEI MAX (Polyscience) transfection reagent. Cell supernatants were harvested and clarified after 3 or 6 days and protein was purified using protein A chromatography (Cytiva). This antibody was validated to bind to the receptor binding domain of SARS-CoV-2 spike protein based on biolayer interferometry data in this work.
4. Validation of SARS-CoV-2 antibody B38 is described here: Wu, Y. et al. Science 2020. Genes encoding this antibody were ordered from GenScript and cloned into pCMV/R. Antibodies were expressed by transient co-transfection of both heavy and light chain

plasmids in Expi293F cells using PEI MAX (Polyscience) transfection reagent. Cell supernatants were harvested and clarified after 3 or 6 days and protein was purified using protein A chromatography (Cytiva). This antibody was validated to bind to the receptor binding domain of SARS-CoV-2 spike protein based on biolayer interferometry data in this work.

5. Validation of SARS-CoV-2 antibody CV30 is described here: Hurlburt, N.K. et al. Nat Commun 2020. Genes encoding this antibody were ordered from GenScript and cloned into pCMV/R. Antibodies were expressed by transient co-transfection of both heavy and light chain plasmids in Expi293F cells using PEI MAX (Polyscience) transfection reagent. Cell supernatants were harvested and clarified after 3 or 6 days and protein was purified using protein A chromatography (Cytiva). This antibody was validated to bind to the receptor binding domain of SARS-CoV-2 spike protein based on biolayer interferometry data in this work.

6. According to manufacturer, sequenced and validated via immunoblotting, immunostaining, and immunoprecipitation.

7. According to manufacturer, sequenced and validated via ELISA.

8. According to manufacturer, this polyclonal goat anti-mouse IgG antibody has no cross-reactivity against non-immunoglobulin serum proteins. Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis.

Eukaryotic cell lines

Policy information about [cell lines](#)

Cell line source(s)	HEK293T/17 (ATCC, CRL-11268). HEK-ACE2 (BEI Resources, NR-52511). HEK293F (Invitrogen, K9000-01). Epi293F (Life Technologies, A14527). Vero E6 (ATCC, CRL-1586). Vero-TMPRSS2 (Siyuan Ding lab). Vero-hACE2-TMPRSS2 (Barney Graham lab).
Authentication	Cells were not further authenticated in the laboratory.
Mycoplasma contamination	All cells were tested negative for Mycoplasma by the provider, and it was not further confirmed in the laboratory.
Commonly misidentified lines (See ICLAC register)	No commonly misidentified lines were used in this study.

Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics	Serum specimens were derived from excess plasma or sera from adults (>18yo) of both genders kindly provided by the Director of the Clinical Chemistry Division, the hospital of University of Washington. All anonymized donor specimens were provided de-identified.
Recruitment	The donors consented to have their excess specimens be used for other experimental studies, they could be transferred to our study without additional consent.
Ethics oversight	The Clinical Chemistry Division, the hospital of University of Washington, with the approval by the University of Washington Human Subjects Division

Note that full information on the approval of the study protocol must also be provided in the manuscript.